Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial
Due to their anatomical locations, optic pathway gliomas (OPGs) can rarely be cured by resection. Given the importance of preserving visual function, we analyzed radiological and visual acuity (VA) outcomes for the type II RAF inhibitor tovorafenib in the OPG subgroup of the phase 2 FIREFLY-1 trial....
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
19 December 2024
|
| In: |
Neuro-Oncology
Year: 2025, Jahrgang: 27, Heft: 5, Pages: 1341-1355 |
| ISSN: | 1523-5866 |
| DOI: | 10.1093/neuonc/noae274 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1093/neuonc/noae274
|
| Verfasserangaben: | Karsten Nysom, Lindsay B Kilburn, Sarah E S Leary, Daniel B Landi, Evelien de Vos-Kerkhof, Sébastien Perreault, Olaf Witt, David S Ziegler, Pablo Hernáiz Driever, Andrea T Franson, Patricia A Baxter, Nicholas S Whipple, Cassie Kline, Devorah Segal, Nada Jabado, Simon Bailey, Geoffrey McCowage, Jordan R Hansford, Dong-Anh Khuong-Quang, Nicholas G Gottardo, Timothy Hassall, Jung Woo Han, Michal Yalon Oren, Susan N Chi, Jiaheng Qiu, Daniel Da Costa, Sandya Govinda Raju, Peter Manley, and Darren Hargrave |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1940609429 | ||
| 003 | DE-627 | ||
| 005 | 20251106160150.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 251106s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/neuonc/noae274 |2 doi | |
| 035 | |a (DE-627)1940609429 | ||
| 035 | |a (DE-599)KXP1940609429 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Nysom, Karsten |e VerfasserIn |0 (DE-588)1380939674 |0 (DE-627)1940609615 |4 aut | |
| 245 | 1 | 0 | |a Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial |c Karsten Nysom, Lindsay B Kilburn, Sarah E S Leary, Daniel B Landi, Evelien de Vos-Kerkhof, Sébastien Perreault, Olaf Witt, David S Ziegler, Pablo Hernáiz Driever, Andrea T Franson, Patricia A Baxter, Nicholas S Whipple, Cassie Kline, Devorah Segal, Nada Jabado, Simon Bailey, Geoffrey McCowage, Jordan R Hansford, Dong-Anh Khuong-Quang, Nicholas G Gottardo, Timothy Hassall, Jung Woo Han, Michal Yalon Oren, Susan N Chi, Jiaheng Qiu, Daniel Da Costa, Sandya Govinda Raju, Peter Manley, and Darren Hargrave |
| 264 | 1 | |c 19 December 2024 | |
| 300 | |a 15 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 06.11.2025 | ||
| 520 | |a Due to their anatomical locations, optic pathway gliomas (OPGs) can rarely be cured by resection. Given the importance of preserving visual function, we analyzed radiological and visual acuity (VA) outcomes for the type II RAF inhibitor tovorafenib in the OPG subgroup of the phase 2 FIREFLY-1 trial.FIREFLY-1 investigated the efficacy (arm 1, n = 77), safety, and tolerability (arms 1/2) of tovorafenib (420 mg/m2 once weekly; 600 mg maximum) in patients with BRAF-altered relapsed/refractory pediatric low-grade glioma (pLGG). In this post hoc analysis, anti-tumor activity and VA were analyzed in arm 1 patients with OPG. Anti-tumor activity was independently assessed per Response Assessment in Neuro-Oncology high-grade glioma (RANO-HGG), Response Assessment in Pediatric Neuro-Oncology-LGG (RAPNO), and RANO-LGG criteria. The data cutoff was June 5, 2023.Forty-two of 77 patients had OPGs; 35 of 42 had ≥2 VA assessments. The overall response rate in the OPG subgroup according to RANO-HGG, RAPNO, and RANO-LGG criteria were 64%, 50%, and 55%, with clinical benefit rates of 95%, 88%, and 90%, respectively. VA per patient was preserved for 80% of patients; 31% demonstrated improved VA; VA per eye was preserved in 87%, with 27% improving. The safety profile in the arm 1 OPG subgroup was similar to the overall FIREFLY-1 safety analysis set.Tovorafenib demonstrated anti-tumor activity in relapsed/refractory BRAF-altered OPG across radiological assessment criteria and was generally well tolerated. Importantly, vision remained stable or improved in most patients. | ||
| 700 | 1 | |a Kilburn, Lindsay B |e VerfasserIn |4 aut | |
| 700 | 1 | |a Leary, Sarah E S |e VerfasserIn |4 aut | |
| 700 | 1 | |a Landi, Daniel B |e VerfasserIn |4 aut | |
| 700 | 1 | |a de Vos-Kerkhof, Evelien |e VerfasserIn |4 aut | |
| 700 | 1 | |a Perreault, Sébastien |e VerfasserIn |4 aut | |
| 700 | 1 | |a Witt, Olaf |d 1965- |e VerfasserIn |0 (DE-588)17275030X |0 (DE-627)697681750 |0 (DE-576)133607410 |4 aut | |
| 700 | 1 | |a Ziegler, David S |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hernáiz Driever, Pablo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Franson, Andrea T |e VerfasserIn |4 aut | |
| 700 | 1 | |a Baxter, Patricia A |e VerfasserIn |4 aut | |
| 700 | 1 | |a Whipple, Nicholas S |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kline, Cassie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Segal, Devorah |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jabado, Nada |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bailey, Simon |e VerfasserIn |4 aut | |
| 700 | 1 | |a McCowage, Geoffrey |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hansford, Jordan R |e VerfasserIn |4 aut | |
| 700 | 1 | |a Khuong-Quang, Dong-Anh |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gottardo, Nicholas G |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hassall, Timothy |e VerfasserIn |4 aut | |
| 700 | 1 | |a Han, Jung Woo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Yalon Oren, Michal |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chi, Susan N |e VerfasserIn |4 aut | |
| 700 | 1 | |a Qiu, Jiaheng |e VerfasserIn |4 aut | |
| 700 | 1 | |a Da Costa, Daniel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Govinda Raju, Sandya |e VerfasserIn |4 aut | |
| 700 | 1 | |a Manley, Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hargrave, Darren R. |e VerfasserIn |0 (DE-588)1342764412 |0 (DE-627)1903094976 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neuro-Oncology |d Oxford : Oxford Univ. Press, 1999 |g 27(2025), 5, Seite 1341-1355 |h Online-Ressource |w (DE-627)357167341 |w (DE-600)2094060-9 |w (DE-576)318041839 |x 1523-5866 |7 nnas |a Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial |
| 773 | 1 | 8 | |g volume:27 |g year:2025 |g number:5 |g pages:1341-1355 |g extent:15 |a Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial |
| 856 | 4 | 0 | |u https://doi.org/10.1093/neuonc/noae274 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20251106 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 17275030X |a Witt, Olaf |m 17275030X:Witt, Olaf |d 910000 |d 910500 |e 910000PW17275030X |e 910500PW17275030X |k 0/910000/ |k 1/910000/910500/ |p 7 | ||
| 999 | |a KXP-PPN1940609429 |e 479775592X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Karsten Nysom, Lindsay B Kilburn, Sarah E S Leary, Daniel B Landi, Evelien de Vos-Kerkhof, Sébastien Perreault, Olaf Witt, David S Ziegler, Pablo Hernáiz Driever, Andrea T Franson, Patricia A Baxter, Nicholas S Whipple, Cassie Kline, Devorah Segal, Nada Jabado, Simon Bailey, Geoffrey McCowage, Jordan R Hansford, Dong-Anh Khuong-Quang, Nicholas G Gottardo, Timothy Hassall, Jung Woo Han, Michal Yalon Oren, Susan N Chi, Jiaheng Qiu, Daniel Da Costa, Sandya Govinda Raju, Peter Manley, and Darren Hargrave"]},"origin":[{"dateIssuedDisp":"19 December 2024","dateIssuedKey":"2024"}],"id":{"eki":["1940609429"],"doi":["10.1093/neuonc/noae274"]},"recId":"1940609429","type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"display":"Nysom, Karsten","role":"aut","family":"Nysom","given":"Karsten"},{"role":"aut","family":"Kilburn","display":"Kilburn, Lindsay B","given":"Lindsay B"},{"given":"Sarah E S","role":"aut","family":"Leary","display":"Leary, Sarah E S"},{"role":"aut","family":"Landi","display":"Landi, Daniel B","given":"Daniel B"},{"display":"de Vos-Kerkhof, Evelien","family":"de Vos-Kerkhof","role":"aut","given":"Evelien"},{"role":"aut","family":"Perreault","display":"Perreault, Sébastien","given":"Sébastien"},{"given":"Olaf","family":"Witt","role":"aut","display":"Witt, Olaf"},{"given":"David S","display":"Ziegler, David S","family":"Ziegler","role":"aut"},{"display":"Hernáiz Driever, Pablo","family":"Hernáiz Driever","role":"aut","given":"Pablo"},{"given":"Andrea T","role":"aut","family":"Franson","display":"Franson, Andrea T"},{"given":"Patricia A","display":"Baxter, Patricia A","family":"Baxter","role":"aut"},{"role":"aut","family":"Whipple","display":"Whipple, Nicholas S","given":"Nicholas S"},{"given":"Cassie","display":"Kline, Cassie","family":"Kline","role":"aut"},{"given":"Devorah","role":"aut","family":"Segal","display":"Segal, Devorah"},{"given":"Nada","display":"Jabado, Nada","family":"Jabado","role":"aut"},{"given":"Simon","family":"Bailey","role":"aut","display":"Bailey, Simon"},{"given":"Geoffrey","display":"McCowage, Geoffrey","role":"aut","family":"McCowage"},{"role":"aut","family":"Hansford","display":"Hansford, Jordan R","given":"Jordan R"},{"given":"Dong-Anh","family":"Khuong-Quang","role":"aut","display":"Khuong-Quang, Dong-Anh"},{"given":"Nicholas G","role":"aut","family":"Gottardo","display":"Gottardo, Nicholas G"},{"given":"Timothy","family":"Hassall","role":"aut","display":"Hassall, Timothy"},{"display":"Han, Jung Woo","family":"Han","role":"aut","given":"Jung Woo"},{"display":"Yalon Oren, Michal","role":"aut","family":"Yalon Oren","given":"Michal"},{"display":"Chi, Susan N","role":"aut","family":"Chi","given":"Susan N"},{"display":"Qiu, Jiaheng","role":"aut","family":"Qiu","given":"Jiaheng"},{"family":"Da Costa","role":"aut","display":"Da Costa, Daniel","given":"Daniel"},{"given":"Sandya","display":"Govinda Raju, Sandya","family":"Govinda Raju","role":"aut"},{"given":"Peter","display":"Manley, Peter","family":"Manley","role":"aut"},{"given":"Darren R.","role":"aut","family":"Hargrave","display":"Hargrave, Darren R."}],"note":["Gesehen am 06.11.2025"],"language":["eng"],"physDesc":[{"extent":"15 S."}],"title":[{"title":"Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial","title_sort":"Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial"}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Neuro-Oncology","subtitle":"official journal of the World Federation of Neuro-Oncology","title":"Neuro-Oncology"}],"part":{"extent":"15","issue":"5","year":"2025","pages":"1341-1355","volume":"27","text":"27(2025), 5, Seite 1341-1355"},"pubHistory":["1.1999 -"],"note":["Gesehen am 21.07.23"],"language":["eng"],"disp":"Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trialNeuro-Oncology","origin":[{"publisher":"Oxford Univ. Press ; Duke University Medical Center","dateIssuedKey":"1999","publisherPlace":"Oxford ; Durham, NC","dateIssuedDisp":"1999-"}],"id":{"issn":["1523-5866"],"zdb":["2094060-9"],"eki":["357167341"]},"recId":"357167341","type":{"bibl":"periodical","media":"Online-Ressource"}}]} | ||
| SRT | |a NYSOMKARSTRADIOGRAPH1920 | ||